These 10 Firms Just Beat the Market Today

2. Akero Therapeutics, Inc. (NASDAQ:AKRO)

Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news that it was exploring a sale.

According to a report by StreetInsider, Akero Therapeutics, Inc. (NASDAQ:AKRO) is now in talks with an investment bank to assist with the process. However, it added that the company’s early interest and strategic review might not necessarily translate to a sale.

In its latest earnings release, Akero Therapeutics, Inc. (NASDAQ:AKRO) widened its net loss by 32.6 percent to $70.7 million from $53.3 million in the same period last year.

Operating expenses surged by 34.9 percent to $80.88 million from $59.95 million year-on-year. Net loss per common share was at 90 cents, similar to the same period a year ago.

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH).